These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38129219)

  • 1. Mifepristone Use Among Obstetrician-Gynecologists in Massachusetts: Prevalence and Predictors of Use.
    Newton-Hoe E; Lee A; Fortin J; Goldberg AB; Janiak E; Neill S
    Womens Health Issues; 2024; 34(2):135-141. PubMed ID: 38129219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of early pregnancy loss among obstetrician-gynecologists in Massachusetts and barriers to mifepristone use.
    Neill S; Hoe E; Fortin J; Goldberg AB; Janiak E
    Contraception; 2023 Oct; 126():110108. PubMed ID: 37394110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between abortion restrictions and patient-centered care for early pregnancy loss at US obstetrics-gynecology residency programs.
    Phillips AM; Rachad S; Flink-Bochacki R
    Am J Obstet Gynecol; 2023 Jul; 229(1):41.e1-41.e10. PubMed ID: 37003363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mifepristone use for early pregnancy loss: A qualitative study of barriers and facilitators among OB/GYNS in Massachusetts, USA.
    Neill S; Mokashi M; Goldberg A; Fortin J; Janiak E
    Perspect Sex Reprod Health; 2023 Sep; 55(3):210-217. PubMed ID: 37394759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abortion Stigma as a Barrier to Mifepristone Use among Obstetrician-Gynecologists in Alabama for Early Pregnancy Loss.
    Mokashi M; Boulineaux C; Janiak E; Boozer M; Neill S
    South Med J; 2024 Aug; 117(8):504-509. PubMed ID: 39094802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced Abortion Provision Among a National Sample of Obstetrician-Gynecologists.
    Grossman D; Grindlay K; Altshuler AL; Schulkin J
    Obstet Gynecol; 2019 Mar; 133(3):477-483. PubMed ID: 30741798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Early Pregnancy Loss Management Between States With Restrictive and Supportive Abortion Policies.
    Tal E; Paul R; Dorsey M; Madden T
    Womens Health Issues; 2023; 33(2):126-132. PubMed ID: 36379879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating abortion provision and abortion referrals among United States obstetrician-gynecologists in private practice.
    Desai S; Jones RK; Castle K
    Contraception; 2018 Apr; 97(4):297-302. PubMed ID: 29174883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mifepristone: A Safe Method of Medical Abortion and Self-Managed Medical Abortion in the Post-Roe Era.
    Schmidt EO; Katz A; Stein RA
    Am J Ther; 2022 Sep-Oct 01; 29(5):e534-e543. PubMed ID: 35994387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obstetrician-gynecologist willingness to provide medication abortion with removal of the in-person dispensing requirement for mifepristone.
    Daniel S; Schulkin J; Grossman D
    Contraception; 2021 Jul; 104(1):73-76. PubMed ID: 33811840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The integration of abortion into obstetrician-gynecologists' practice after comprehensive family planning resident training.
    Turk J; Landy U; Preskill F; Adler A; Steinauer J
    Contraception; 2021 Oct; 104(4):337-343. PubMed ID: 34119457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for obstetricians and gynecologists to advance reproductive autonomy in a post-Roe landscape.
    Dahl CM; Turok D; Heuser CC; Sanders J; Elliott S; Pangasa M
    Am J Obstet Gynecol; 2024 Feb; 230(2):226-234. PubMed ID: 37536485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roe 2022: It's Not 1972.
    Darney PD; Landy U
    Obstet Gynecol; 2022 Oct; 140(4):554-556. PubMed ID: 35861336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US clinicians' perspectives on how mifepristone regulations affect access to medication abortion and early pregnancy loss care in primary care.
    Srinivasulu S; Yavari R; Brubaker L; Riker L; Prine L; Rubin SE
    Contraception; 2021 Jul; 104(1):92-97. PubMed ID: 33910031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US Obstetrician-Gynecologists' Perceived Impacts of Post-Dobbs v Jackson State Abortion Bans.
    Sabbath EL; McKetchnie SM; Arora KS; Buchbinder M
    JAMA Netw Open; 2024 Jan; 7(1):e2352109. PubMed ID: 38231510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ob/Gyn training in abortion care: results from a national survey.
    Jackson CB; Foster AM
    Contraception; 2012 Oct; 86(4):407-12. PubMed ID: 22560184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it an abortion: Classification of pregnancy-ending interventions after 24 weeks in the presence of lethal fetal anomalies.
    Flink-Bochacki R; McLeod C; Lipe H; Rapkin RB; Rubin SL; Heuser CC
    Contraception; 2024 Sep; 137():110492. PubMed ID: 38763276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy complications and loss: an observational survey comparing anesthesiologists and obstetrician-gynecologists.
    Barnett NR; George RM; Hatter KH; Janosy NR; Vizzini SJ; Singh S; Lee RE; Wolf BJ; Cabrera C; Duhachek-Stapelman AL; Katz D
    J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2311072. PubMed ID: 38326280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mifepristone on abortion access in the United States.
    Finer LB; Wei J
    Obstet Gynecol; 2009 Sep; 114(3):623-630. PubMed ID: 19701044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second- and Third-Trimester Medical Abortion Providers and Services in 2019: Results From the Canadian Abortion Provider Survey.
    Renner R; Ennis M; Guilbert E; Roy G; Barrett J
    J Obstet Gynaecol Can; 2022 Jun; 44(6):690-699. PubMed ID: 35183788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.